ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Polygenic risk-based prediction of heart failure in young patients with atrial fibrillation: an analysis from UK Biobank.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Clinical utility of polygenic risk scores in cardiovascular disorders.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
- Polygenic risk scores for cardiovascular disease: clinical utility and limitations.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Integrating Polygenic Scores with Clinical, Lifestyle, and Social Risk Factors to Improve Heart Failure Risk Prediction.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2026Article
- Comprehensive evaluation of the prevalent insulin resistance indices for pan-cancer incidence and mortality prediction.Tropical medicine and health · 2025Article
- Vascular cell adhesion molecule 1: a marker for atrial fibrillation and heart failure risk.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Polygenic risk-based prediction of heart failure in young patients with atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- When age meets genetics: refining heart failure risk prediction in young atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Genomic medicine for heart failure prediction in patients with atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Genetic risk uncovers early onset heart failure in clinically low-risk young adults with atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
aimsHeart failure (HF) is the most concerning morbidity in atrial fibrillation (AF) through mutual influence on a poor prognosis. A polygenic risk score (PRS) has recently been proposed to improve the risk prediction for cardiovascular disease. The additive predictive role of PRS for incident HF in patients with AF who inherently carry a high risk of HF is unknown. METHODS AND
resultsFrom the UK Biobank, we identified 21 167 White Caucasian participants with newly diagnosed AF without a prior history of HF. The PRS for HF was constructed using genetic instruments from previous genome-wide association studies. The primary outcome was the occurrence of incident HF. The prediction of incident HF was evaluated using the tertile categorization of PRS for HF (low vs. moderate-high PRS) across the entire AF cohort, as well as within age subgroups (young AF, age <60 years; old AF, age ≥60 years, respectively). The mean age was 69.0 ± 6.9 years in the total population (55.2 ± 3.9 years in age <60 years; 70.7 ± 5.0 years in age ≥60 years group). During a median follow-up of 3.8 (1.4-7.2) years, the incidence rate (1000-patient year) of HF was 29.9. In the total population, AF patients with moderate-high PRS for HF were associated with a higher risk of HF than those with low PRS for HF [adjusted hazard ratio (HR) 1.18 (95% confidence interval (CI), 1.05-1.32), P = 0.005]. The higher risk of HF in the moderate-high PRS group was particularly accentuated in young AF patients: adjusted HR, 2.14 (95% CI 1.29-3.57) in young AF, and 1.13 (95% CI 1.01-1.27) in old AF, P-for-interaction = 0.015. In young AF, the onset of incident HF was earlier in those with the moderate-high PRS group [median time from AF diagnosis to incident HF, 4.2 (0.8-7.1) years in low PRS vs. 1.5 (0.3-4.7) years in the moderate-high PRS group, P = 0.001]. The prediction of HF was significantly improved by adding PRS to the clinical risk factors for HF, especially in young AF patients, with a net reclassification improvement of 29.7% (P = 0.003).
conclusionPRS for HF can significantly improve the prediction of incident HF in patients with AF, especially in the young population, providing clinical utility of an individualized approach to integrated management of AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.